Last reviewed · How we verify
NCT04145388
Family History Study on Cancer Risk
NA trial testing online cancer risk assessment in Lynch Syndrome in 18,623 participants. Status unknown.
15 March 2023
Quick facts
| Lead sponsor | Kaiser Permanente |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 18,623 |
| Start date | 1 July 2020 |
| Primary completion | 15 March 2023 |
| Estimated completion | 31 August 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- online cancer risk assessment
- Usual care
Conditions studied
- Lynch Syndrome — all drugs for Lynch Syndrome →
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Breast Cancer — all drugs for Breast Cancer →
- Ovarian Cancer — all drugs for Ovarian Cancer →
Sponsor
Kaiser Permanente — full company profile →
Who can join
Adults 25 to 75, any sex, with Lynch Syndrome or Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to identify the optimal method to recognize, risk stratify, and provide follow-up care for individuals at risk of hereditary cancer. The study team will conduct a Hybrid Type II comparative effectiveness-implementation trial, with a mixed methods component and process/formative evaluations for stakeholder engagement. The study team will evaluate three methods for identifying and risk-stratifying individuals at risk of hereditary cancer and providing post-risk stratification longitudinal care.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04145388
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lynch Syndrome
Currently open trials in the same condition.
- NCT07163403 — First in Human Pilot Study to Assess the Safety and Efficacy of Dendritic Cells Loaded With Frameshift Derived Neopeptid · Phase 1 · recruiting
- NCT06582914 — Lynch Syndrome Integrative Epidemiology and Genetics · recruiting
- NCT06447961 — PSYLIVED: the Psychological Impacts of Living With an Inherited Colorectal Cancer Predisposition Syndrome · recruiting
- NCT05963191 — CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome · NA · recruiting
- NCT06712095 — Video Capsule Examination in Patients With Lynch Syndrome · NA · recruiting
Other Kaiser Permanente trials
Trials by the same sponsor.
- NCT07522645 — Adherence to Dyslipidemia Therapy: Harnessing Evidence From Randomized Evaluations in AtheroSclerotic CardioVascular Dis · NA · not yet recruiting
- NCT07474038 — AI-Supported Cognitive Rehabilitation for Older Adults With Mild Cognitive Impairment · NA · enrolling by invitation
- NCT07467668 — Infusing Needed Iron to Target Insufficiency in Adults Treated for Evidence of Heart Failure · NA · not yet recruiting
- NCT07216859 — Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT Echo-AI) · NA · not yet recruiting
- NCT07264062 — MetSense Pilot and Feasibility · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04145388 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kaiser Permanente
- Last refreshed: 14 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04145388.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing